GLPwatch
Papers (12034)
Page 113 of 201, ranked by citation count.
- Characterization of low-level D-amino acid isomeric impurities of Semaglutide using liquid chromatography-high resolution tandem mass spectrometry.
- Liraglutide improves sevoflurane-induced postoperative cognitive dysfunction via activating autophagy and inhibiting apoptosis.
- Intensive management of obesity in people with Prader-Willi syndrome.
- [Effect of glucagon-like peptide 1 receptor agonists on body fat redistribution and muscle mass in overweight and obese type 2 diabetic patients].
- Semaglutide once-weekly: improved efficacy with a new safety warning.
- Weight Gain Was Associated With Worsening Glycemia and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes Independent of Diabetes Medication in the GRADE Randomized Controlled Trial.
- Albiglutide for the treatment of type 2 diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Resolution of symptoms of binge eating disorder associated with semaglutide treatment for obesity and type 1 diabetes.
- Exendin-4, a glucagon-like peptide-1 receptor agonist, alleviates muscular dysfunction and wasting in a streptozotocin-induced diabetic mouse model compared to metformin.
- Seizure recurrence after GLP-1 receptor agonist initiation in adults with epilepsy.
- Acute Kidney Injury Occurring in a Patient Initiated on Dulaglutide.
- [<sup>18</sup>F]FB(ePEG12)12-exendin-4 noninvasive imaging of insulinoma negative for insulin immunostaining on specimen from endoscopic ultrasonography-guided fine needle aspiration: a case report with review of literature.
- Spinal cord-wide structural disruption in type 2 diabetes rescued by exenatide "a glucagon-like peptide-1 analogue" via down-regulating inflammatory, oxidative stress and apoptotic signaling pathways.
- Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting.
- Add-on value of tirzepatide versus semaglutide.
- 18F-Labelled exendin to image GLP-1 receptor-expressing tissues: from niche to blockbuster?
- Prolonged Semaglutide Treatment Reveals Stage-Dependent Changes to Feeding Behavior and Metabolic Adaptations in Male Mice.
- Diabetes drugs activate neuroprotective pathways in models of neonatal hypoxic-ischemic encephalopathy.
- Therapeutic Potential of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction (HFpEF) in Obese Patients.
- Glucagon-like Peptide-1 Receptor Agonist Use and Risk of Cataract Development.
- GLP-1R agonist therapy and vaccine response: Neglected implications.
- Association of semaglutide with less limb events in people with type 2 diabetes and peripheral artery disease or foot ulcers: An observational study comparing matched cohorts.
- Predictive factors associated with glycaemic response to exenatide in Chinese patients with type 2 diabetes mellitus.
- Synthesis and Evaluation of a Series of Long-Acting Glucagon-Like Peptide-1 (GLP-1) Pentasaccharide Conjugates for the Treatment of Type 2 Diabetes.
- Liraglutide, a glucagon-like peptide-1 receptor agonist, induces ADAM10-dependent ectodomain shedding of RAGE via AMPK activation in human aortic endothelial cells.
- Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.
- Renoprotective Effect of Liraglutide Is Mediated via the Inhibition of TGF-Beta 1 in an LLC-PK1 Cell Model of Diabetic Nephropathy.
- Effect of liraglutide on endoplasmic reticulum stress in the renal tissue of type 2 diabetic rats.
- Oral semaglutide in type 2 diabetes mellitus: Comprehensive review, critical appraisal and clinical consideration of its use in India.
- L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease.
- The Antidiabetic Drug Liraglutide Minimizes the Non-Cholinergic Neurotoxicity of the Pesticide Mipafox in SH-SY5Y Cells.
- Amylin analogs for the treatment of obesity without diabetes: present and future.
- Simultaneous quantitative determination of liraglutide and insulin degludec in rat plasma by liquid chromatography-tandem mass spectrometry method and its application.
- Novel oral agents in anti-obesity pharmacotherapy: A narrative review.
- Modeling potential cost-effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity.
- Managing insulin resistance: role of liraglutide.
- Dietary salt promotes cognition impairment through GLP-1R/mTOR/p70S6K signaling pathway.
- Cardiovascular outcomes and safety of semaglutide in non-overweight populations with type 2 diabetes: a comparison with dipeptidyl peptidase 4 inhibitors.
- Exenatide pretreatment improved graft function in nonhuman primate islet recipients compared to treatment after transplant only.
- Glucagon-Like Peptide-1 Receptor Agonist Therapy Does Not Increase Gastrointestinal Adverse Events in Patients with Inflammatory Bowel Disease.
- Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial.
- HbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis.
- Favorable Effect on Blood Volume Control in Hemodialysis Patients with Type 2 Diabetes after Switching from Insulin Therapy to Liraglutide, a Human Glucagon-like Peptide-1 Analog--Results from a Pilot Study in Japan-.
- Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly.
- Redox-active injectable gel using polyion complex to achieve sustained release of exenatide and enhance therapeutic efficacy for the treatment of type 2 diabetes.
- Effects of oral semaglutide on cardiovascular outcomes: A systematic review and meta-analysis.
- Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China.
- Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea.
- Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase.
- Eosinophilic Panniculitis Following the Subcutaneous Injection of Exenatide Extended-Release.
- Beyond Glycemic Control: GLP-1 Receptor Agonists and Their Impact on Calcium Homeostasis in Real-World Patients.
- Advances in the treatment of type 2 diabetes: impact of dulaglutide.
- Antinociceptive Behavior, Glutamine/Glutamate, and Neopterin in Early-Stage Streptozotocin-Induced Diabetic Neuropathy in Liraglutide-Treated Mice under a Standard or Enriched Environment.
- Evaluating remission of type 2 diabetes using a metabolic intervention including fixed-ratio insulin degludec and liraglutide: A randomized controlled trial.
- Hearing protection and damage mitigation in Chinchillas exposed to repeated low-intensity blasts.
- Detection of impaired cognitive function in rat with hepatosteatosis model and improving effect of GLP-1 analogs (exenatide) on cognitive function in hepatosteatosis.
- Treatment of Bile Acid Diarrhea With Glucagon-Like Peptide 1 Receptor Agonists: A Promising Yet Understudied Approach.
- Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis.
- Do interactions between protein and phospholipids influence the release behavior from lipid-based exenatide depot systems?